危重婴儿百日咳感染:荟萃分析与死亡评分验证
该研究系统检索2000年1月至2024年6月PubMed、EMBASE和LiSSa数据库的观察性研究,纳入17项研究共2725例患儿,采用REML随机效应模型合并分析。PICU百日咳患儿合并死亡率19%(95%CI 12-26;I2=96),机械通气、连续性肾脏替代治疗和体外膜肺氧合支持的合并发生率分别为55%(95%CI 40-70;I2=98)、15%(95%CI 3-27;I2=95)和8%(95%CI 3-12;I2=93)。死亡危险因素包括心率增快、肺动脉高压、惊厥和白细胞计数升高。在83例单中心队列(中位年龄45天,IQR 30-55)中验证,死亡率为12%,上述危险因素与死亡显著相关;据此建立的包含年龄<30天、心率>200/min、WBC>30 G/l的死亡预测评分AUC为0.92(95%CI 0.86-0.99)。
要点
- PICU百日咳患儿合并死亡率为19%(95%CI 12-26;I2=96),机械通气合并发生率55%(95%CI 40-70;I2=98)。
- 死亡危险因素包括心率增快、肺动脉高压、惊厥和白细胞计数升高,在83例单中心队列中与死亡显著相关。
- 死亡预测评分纳入年龄<30天、心率>200/min、WBC>30 G/l,AUC 0.92(95%CI 0.86-0.99)。
- 连续性肾脏替代治疗和体外膜肺氧合支持的合并发生率分别为15%(95%CI 3-27;I2=95)和8%(95%CI 3-12;I2=93)。
适用人群与场景
- 因重症百日咳收入PICU的婴儿;荟萃分析纳入17项观察性研究共2725例患者,验证队列为1996年1月至2020年12月收入三级医院PICU的83例患儿(中位年龄45天,IQR 30-55)。
诊断标准与关键阈值
- 死亡预测评分纳入年龄<30天、心率>200/min、WBC>30 G/l三项指标,AUC 0.92(95%CI 0.86-0.99)。
研究设计与关键结果
- 研究类型为荟萃分析加单中心队列验证;检索2000年1月至2024年6月PubMed、EMBASE和LiSSa数据库,816条唯一引文,最终纳入17项观察性研究共2725例患者。
- 合并死亡率19%(95%CI 12-26;I2=96);机械通气合并发生率55%(95%CI 40-70;I2=98),连续性肾脏替代治疗15%(95%CI 3-27;I2=95),体外膜肺氧合支持8%(95%CI 3-12;I2=93)。
- 荟萃分析识别的死亡危险因素为心率增快、肺动脉高压、惊厥和白细胞计数升高;在83例单中心队列(中位年龄45天,IQR 30-55)中死亡率为12%,上述危险因素与死亡显著相关。
- 基于年龄<30天、心率>200/min、WBC>30 G/l建立死亡预测评分,AUC 0.92(95%CI 0.86-0.99)。
证据类型、等级与局限
- 证据类型为观察性研究的荟萃分析及单中心队列验证;研究方案注册于PROSPERO(CRD42024582057)。
- 合并发生率存在高度异质性:机械通气I2=98、连续性肾脏替代治疗I2=95、体外膜肺氧合I2=93、死亡率I2=96。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该简易评分可用于评估收入PICU的婴儿百日咳感染严重程度,准确的风险分层可能有助于及时治疗危重患者,从而可能改善结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite widespread vaccination programs, pertussis continues circulating within populations and remains a life-threatening infection in infants. While several mortality risk factors have been described, a comprehensive synthesis is lacking. We conducted a meta-analysis of studies investigating mortality risk factors in Pertussis infections and validated those factors in a large cohort.
METHODS: Observational studies published in English were systematically searched in PubMed, EMBASE, and LiSSa databases from 01/2000 to 06/2024. The search yielded 816 unique citations. The primary outcome was mortality before discharge from the Pediatric Intensive Care Unit (PICU). Two independent reviewers assessed the risk of bias and extracted data. A REML-random effect model was used to calculate pooled prevalence and conduct the analysis. The identified risk factors were subsequently evaluated in a monocentric cohort of patients admitted to a tertiary hospital's PICU for severe pertussis between January 1996 and December 2020. Data analysis was conducted between June and August 2024.
RESULTS: Seventeen studies, including 2,725 patients, met the inclusion criteria. The pooled prevalence of mechanical ventilation, continuous renal replacement therapy, and Extracorporeal Membrane Oxygenation support were 55% (95% CI: 40-70; I2 = 98), 15% (95% CI: 3-27; I2 = 95), and 8% (95% CI: 3-12; I2 = 93), respectively. The pooled mortality incidence was 19% (95% CI:12-26; I2 = 96). Identified mortality risk factors included elevated heart rate, presence of pulmonary hypertension, presence of seizures, and elevated white blood cell (WBC) count. Validation in an 83-patient cohort (median age: 45 days, IQR: 30-55) revealed a mortality rate of 12%. Risk factors identified in the meta-analysis were significantly associated with non-survival in the cohort. A mortality prediction score was developed incorporating age < 30 days, heart rate > 200/min, and WBC > 30 G/l, achieving an area under the curve of 0.92 (95% CI: 0.86-0.99).
CONCLUSION: This meta-analysis identified a simple yet effective score to assess the severity of pertussis infection in infants admitted to PICU. Accurate risk stratification may enable timely treatment of critically ill patients, potentially improving outcomes.
TRIAL REGISTRATION: The study protocol was registered on PROSPERO: CRD42024582057.
参考来源
- Cousin VL, Caula C, Vignot J, et al. Pertussis infection in critically ill infants: meta-analysis and validation of a mortality score. Crit Care. 2025. PMID: 39930478. doi:10.1186/s13054-025-05300-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。